Page last updated: 2024-08-21

pyrazines and B-Cell Chronic Lymphocytic Leukemia

pyrazines has been researched along with B-Cell Chronic Lymphocytic Leukemia in 108 studies

Research

Studies (108)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	18 (16.67)	29.6817
2010's	26 (24.07)	24.3611
2020's	64 (59.26)	2.80

Authors

Authors	Studies
Armand, P; Arnason, JE; Brown, JR; Crombie, JL; Davids, MS; Fisher, DC; Jacobson, CA; Kim, AI; LaCasce, AS; Lampson, BL; Lowney, JC; Montegaard, J; Ng, SY; Patterson, V; Pazienza, S; Tyekucheva, S; Wang, Z; Weinstock, M	1
Brown, JR; Byrd, JC; Ferrajoli, A; Furman, RR; Ghia, P; Hillmen, P; Jurczak, W; Kuptsova-Clarkson, N; Moslehi, J; Pagel, JM; Patel, P; Sharman, JP; Stephens, DM; Sun, C; Tao, L	1
Gaballa, S; Pinilla-Ibarz, J	1
Brown, JR; Byrd, JC; Cheung, J; Eyre, TA; Furman, RR; Ghia, P; Hamdy, A; Hillmen, P; Izumi, R; Pagel, JM; Patel, P; Schuh, A; Wang, MH; Wierda, WG; Xu, Y	1
Al-Sawaf, O; Fischer, K	1
Trentin, L; Visentin, A	1
Brown, JR	1
Nierman, P	1
Shah, HR; Stephens, DM	1
Allsup, DJ; Arman, M; Booth, Z; Caserta, S; Chacko, AR; Hart, SP; Jarvis, J; Khan, S; Naylor-Adamson, L; Rivero, F	1
Banerji, V; Byrd, JC; Corbett, G; Coutre, S; Cymbalista, F; Egyed, M; Ferrant, E; Flinn, IW; Fogliatto, LM; Follows, G; Ghia, P; Herishanu, Y; Janssens, A; Jurczak, W; Kamdar, M; Karlsson, K; Munir, T; Munugalavadla, V; Pagel, JM; Sharman, JP; Skarbnik, A; Walewska, R; Walker, P; Wang, MH; Wierda, WG; Woyach, JA; Yu, T	1
Ghia, P	1
Borbely, J; Egyed, M; Illes, A; Lueff, S	1
Baran, AM; Barr, PM; Blick-Nitko, SK; Chu, CC; Elliott, MR; Izumi, R; Munugalavadla, V; Peterson, DR; Pinney, JJ; Van DerMeid, KR; Whitehead, HE; Zent, CS	1
Robak, T; Wolska-Washer, A	1
Black, GS; Byrd, JC; Huang, X; Marth, GT; Misra, S; Qiao, Y; Rogers, KA; Stephens, DM; Tarapcsak, S; Woyach, JA	1
Abraham, I; Alrawashdh, N; Erstad, B; McBride, A; Persky, DO; Sweasy, J	1
Brüggemann, M; Cramer, P; Eichhorst, B; Fink, AM; Fischer, K; Franzen, F; Fürstenau, M; Giza, A; Hallek, M; Ritgen, M; Robrecht, S; Schilhabel, A; Schneider, C; Stilgenbauer, S; Tausch, E; Weiss, J	1
Budde, LE; Calvo, R; Champion, R; Coleman, M; Geethakumari, PR; Higgins, K; Lam, S; Levy, MY; Lossos, IS; Ma, S; Patti, C; Strati, P	1
Al-Sawaf, O; Böttcher, S; Brüggemann, M; Cramer, P; Dreger, P; Eichhorst, B; Fink, AM; Fischer, K; Fürstenau, M; Giza, A; Hallek, M; Kneba, M; Kreuzer, KA; Langerbeins, P; Ritgen, M; Robrecht, S; Schetelig, J; Schilhabel, A; Schneider, C; Stilgenbauer, S; Tausch, E; Zhang, C	1
Booth, S; Bye, AP; Cowen, LG; Desborough, MJ; Eyre, TA; Gibbins, JM; Kesavan, M; Kriek, N; Lees, C; Prodger, C; Rawlings, SJ; Sage, T; Shefferd, K	1
DiPippo, AJ; Ferrajoli, A; Lee, J; McGhie, A	1
Azali, L; Bhat, SA; Byrd, JC; Grever, MR; Kittai, AS; Kumar, PS; Palettas, M; Pollauf, AJ; Rogers, KA; Rosen, L; Wiczer, T; Woyach, JA; Zheng, A	1
Bruzzese, A; Filippelli, G; Gentile, M; Iaccino, E; Lucia, E; Martino, EA; Mendicino, F; Morabito, F; Neri, A; Olivito, V; Vigna, E	1
Ghia, P; Hettle, R; Kittai, AS; Miranda, M; Palazuelos-Munoz, S; Roos, J; Shetty, V; Skarbnik, A; Yong, ASM	1
Yaqub, F	1
Awan, FT; Barrientos, J; Brown, JR; Burke, K; Byrd, JC; Chaves, JM; Covey, T; Devereux, S; Frigault, MM; Furman, RR; Ghia, P; Gulrajani, M; Hamdy, A; Hillmen, P; Izumi, R; Martin, P; O'Brien, S; Pagel, JM; Patel, P; Rothbaum, W; Schuh, A; Stephens, DM; Wang, MH; Wierda, WG; Woyach, JA	1
Andersen, BL; Bhat, SA; Blachly, JS; Byrd, JC; Frigault, MM; Gulrajani, M; Hamdy, A; Izumi, R; Jianfar, M; Lozanski, G; Munugalavadla, V; Quah, C; Rogers, KA; Wang, MH; Weiss, DM; Woyach, JA	1
Alsadhan, A; Bibikova, E; Cheung, J; Covey, T; Gaglione, EM; Gulrajani, M; Hamdy, A; Herman, SEM; Izumi, R; Nierman, P; Patel, P; Sun, C; Wiestner, A	1
Bossory Goike, L; Dean, S	1
Bhargava, P; Danilov, AV; Dyer, MJS; Fegan, CD; Herbaux, C; Hillmen, P; Huang, X; Humeniuk, R; Jürgensmeier, JM; Karlin, L; Kio, EA; Mitra, SS; Rule, SA; Walter, HS; Yi, PC; Zhou, Z	1
Ahn, IE; Cheung, J; Covey, T; Farooqui, MZH; Gaglione, EM; Gulrajani, M; Hamdy, A; Harris, HM; Herman, SEM; Izumi, R; Kendall, EK; Maric, I; Nierman, P; Patel, P; Pittaluga, S; Pleyer, C; Stetler-Stevenson, M; Sun, C; Wang, MH; Wiestner, A; Yuan, CM	1
Davids, MS	1
Banerji, V; Byrd, JC; Corbett, G; Coutre, S; Cymbalista, F; Egyed, M; Flinn, IW; Fogliatto, LM; Follows, G; Ghia, P; Herishanu, Y; Izumi, R; Janssens, A; Jurczak, W; Kamdar, M; Karlsson, K; Munir, T; Munugalavadla, V; Pagel, JM; Patel, P; Salles, G; Sharman, JP; Skarbnik, A; Walewska, R; Walker, P; Wang, MH; Wierda, WG; Wong, S; Woyach, JA	1
Chong, EA; Davids, MS; Mato, AR; Roeker, LE; Schuster, SJ; Shadman, M	1
Romero, D	1
Bhalla, S; Gabrilove, J; Sigel, K; Thibaud, S; Tremblay, D; Zimmerman, B	1
Avery, E; Campbell, P; de la Serna, J; Dolan, S; Ghia, P; Illes, A; Jacob, A; Jurczak, W; Kaplan, P; Kozak, T; Kraychok, I; Lee, JH; Liang, W; Lysak, D; Musuraca, G; Patel, P; Pluta, A; Quah, C; Simkovic, M; Wach, M	1
Beylot-Barry, M; Protin, C; Recher, C; Sibaud, V; Vigarios, E; Ysebaert, L	1
Thompson, PA	1
Bertino, EM; Bhat, SA; Bond, DA; Byrd, JC; Fisher, JL; Grever, MR; Huang, Y; Jaglowski, SM; Maddocks, KJ; Owen, DH; Rogers, KA; Ruppert, AS; Woyach, JA	1
Gao, A; Gao, W; Huo, D; Ran, X; Sheng, Z; Song, S; Yu, M; Zhu, H	1
Abhyankar, S; Davids, MS; Le Nouveau, P; Leblond, V; Padhiar, A; Singh, G; Waweru, C	1
Bartoli, L; Messori, A	1
Giannarelli, D; Molica, S; Montserrat, E	1
Danilov, AV; Persky, DO	1
Barrientos, JC; Rhodes, JM	1
Dlugosz-Danecka, M; Ghia, P; Jurczak, W; Scarfò, L	1
Camarero, J; Delgado, J; Enzmann, H; Garcia-Ochoa, B; Gisselbrecht, C; Josephson, F; Lopez-Anglada, L; Papadouli, I; Pignatti, F; Prieto-Fernandez, C; van Hennik, PB	1
Best, S; Danilov, AV; Goodyear, S; Hashiguchi, T; Kittai, AS; Lam, V; Okada, C; Park, B; Persky, DO; Spurgeon, SE; Thurlow, B	1
Ando, K; Ennishi, D; Hayashi, N; Ichikawa, S; Iizumi, S; Izutsu, K; Kato, K; Kawasumi, H; Kumagai, K; Murayama, K; Nagai, H; Patel, P; Shibayama, H; Suzumiya, J; Yamamoto, K	1
Allan, JN; Cheson, BD; Coleman, M; Frigault, MM; Izumi, R; Jones, D; Kipps, TJ; Patel, P; Quah, C; Raman, RK; Rogers, KA; Sharman, JP; Thompson, PA; Wang, MH	1
Barrientos, JC; Brown, JR; Byrd, JC; Devereux, S; Furman, RR; Hamdy, A; Hillmen, P; Izumi, R; Jain, N; Martin, P; O'Brien, S; Pagel, JM; Patel, P; Stephens, DM; Wang, MH; Wierda, WG; Woyach, JA	1
Baek, M; Brown, JR; Byrd, JC; Chernyukhin, N; Christian, B; Dyer, MJS; Furman, RR; Ghia, P; Hamdy, AM; Hillmen, P; Izumi, R; Jurczak, W; Lezhava, T; O'Brien, SM; Owen, RG; Pagel, JM; Patel, P; Rule, S; Sharman, JP; Stephens, DM; Streetly, MJ; Sun, C; Wang, M	1
Abhyankar, S; Davids, MS; Ringshausen, I; Telford, C; Waweru, C	1
Ahn, IE; Baptista, MJ; Blackburn, A; Eik, D; Gaglione, EM; Kendall, EK; Keyvanfar, K; Mhibik, M; Qi, J; Rader, C; Sun, C; Wiestner, A	1
Mato, AR; Thompson, MC	1
Best, S; Danilov, AV; Kittai, A; Lam, V; Liu, T; Orand, K; Spurgeon, SE	1
Woyach, JA	1
Ahn, IE; Brown, JR	1
Blackmon, A; O'Brien, S	1
Li, J; Miao, Y; Xu, W	1
Mulder, TA; Österborg, A; Palma, M	1
Byrd, JC; Chanan-Khan, A; Furman, RR; Garcia-Marco, JA; Ghia, P; Hamdy, A; Higgins, K; Hillmen, P; Illés, A; Izumi, R; Jurczak, W; Kater, AP; Kay, N; Lepretre, S; Mato, A; O'Brien, S; Patel, P; Pinilla-Ibarz, J; Robak, T; Rothbaum, W; Seymour, JF; Sohoni, S; Stilgenbauer, S; Yenerel, MN	1
Kaur, V; Swami, A	1
Golay, J; Introna, M; Ubiali, G	1
Chen, SS; Chiorazzi, N; Covey, T; Dadashian, EL; Herman, SEM; Izumi, R; Krantz, F; Lannutti, BJ; Mora-Jensen, HI; Niemann, CU; Ulrich, R; Wiestner, A	1
Andritsos, LA; Awan, F; Beckwith, K; Byrd, JC; Caligiuri, MA; Cheney, C; Do, P; Flynn, JM; Fraietta, JA; Gordon, A; Johnson, AJ; Jones, JA; June, CH; Lehman, AM; Long, M; Maddocks, KJ; Maus, MV; Mundy, BL; Muthusamy, N; Woyach, JA	1
Ayres, ML; Balakrishnan, K; Cheung, JP; Gandhi, V; Gay, J; Ivan, C; Keating, MJ; Lamothe, B; Marszalek, JR; Morse, J; Nelson, M; Patel, VK; Wierda, WG	1
Dhillon, S; Markham, A	1
Coulter, EM; Cuthill, K; Devereux, S; Folarin, N; Mele, S; Patten, PEM; Pepper, A; Phillips, EH; Townsend, W	1
Khan, Y; O'Brien, S	1
Alhalouli, T; Bueso-Ramos, C; Burger, J; Estrov, Z; Ferrajoli, A; Jain, N; Jain, P; Kanagal-Shamanna, R; Kantarjian, HM; Keating, M; Khoury, JD; Luthra, R; Medeiros, LJ; Patel, KP; Routbort, M; Wierda, W	1
Assouline, S; Awan, FT; Hill, B; Patel-Donnelly, D; Rao, AV; Sharman, JP; Thirman, MJ; Ye, W	1
Awan, FT; Bibikova, E; Brown, JR; Byrd, JC; Charuworn, P; Frigault, MM; Furman, RR; Hamdy, A; Hillmen, P; Izumi, R; Linghu, B; Pagel, JM; Patel, P; Schuh, A; Stephens, DM; Wang, MH; Woyach, J	1
Al, MJ; Geenen, JW; Goettsch, WG; Hövels, AM; Leufkens, HGM; Vreman, RA	1
Burke, RT; Clarke, AS; Currie, KS; Dipaolo, JA; Druker, BJ; Lannutti, BJ; Loriaux, MM; Maciejewski, P; Meadows, S; Mitchell, SA; Spurgeon, SE	1
Abella, S; Boxer, M; Hawkins, M; Hu, J; Klein, L; Kolibaba, K; Sharman, J; Wu, M; Yasenchak, C	1
Awan, FT; Barrientos, JC; Brown, JR; Byrd, JC; Chaves, J; Covey, T; Devereux, S; Diacovo, TG; Fardis, M; Furman, RR; Ghia, P; Hamdy, A; Harrington, B; Hillmen, P; Huang, J; Izumi, R; Johnson, AJ; Johnson, D; Jones, JA; Kaptein, A; Lannutti, BJ; McGreivy, J; O'Brien, S; Pagel, JM; Rothbaum, W; Schuh, A; Stephens, DM; Wang, X; Wierda, WG; Woyach, J	1
Burki, TK	1
Wilson, WH	1
Abella-Dominicis, E; Barr, PM; Cheson, BD; Di Paolo, J; Dreiling, LK; Friedberg, JW; Greenwald, DR; Hawkins, MJ; He, J; Hu, J; Joshi, A; Lee, H; Liem, AK; Mclntyre, RE; O'Brien, SM; Reddy, A; Saylors, GB; Spurgeon, SE	1
Bendell, J; Brown, JR; Derks, IA; Eichhorst, B; Eldering, E; Fernandes, SM; Filvaroff, EH; Garrick, B; Hallek, M; Hege, K; Kater, AP; Kersten, MJ; Michot, JM; Reinhardt, HC; Rodríguez, MS; Ter Burg, J; Thijssen, R; Trowe, T; van Bochove, GG; van Kampen, RJ	1
Dyer, MJ; Salles, GA; Walter, HS	1
Liu, C; Liu, D; Tsui, ST; Wu, J	1
Almejún, MB; Bezares, RF; Borge, M; Cabrejo, M; Colado, A; Dos Santos, P; Elías, EE; Fernández Grecco, H; Gamberale, R; Giordano, M; Podaza, E; Risnik, D; Slavutsky, I; Stanganelli, C	1
Brown, JR; Davids, MS; Deng, J; Fernandes, SM; Isik, E; Letai, A	1
Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A	1
Bhagat, G; Furman, RR; Gardner, JR; Gonen, M; Gueorguiev, VD; Heaney, ML; Manova, K; O'Connor, OA; Paoluzzi, L; Scotto, L	1
Campo, E; Colomer, D; López-Guerra, M; Montserrat, E; Nguyen, M; Pérez-Galán, P; Roué, G; Shore, GC; Villamor, N	1
Agrawal, SG; Gribben, JG; Jia, L; Liu, FT; Movasaghi, Z; Newland, AC; Rehman, IU; Wyatt, PB	1
Chandra, J; Keating, MJ; Miller, CP; Palladino, M; Rudra, S; Wierda, WG	1
Bhattacharya, N; Döhner, H; Führer, M; Idler, IS; Mertens, D; Sarno, A; Stilgenbauer, S; Zenz, T	1
Baou, M; Butterworth, M; Cohen, GM; Dinsdale, D; Dyer, MJ; Eldering, E; Kohlhaas, SL; Majid, A; Vogler, M; Walewska, R	1
Feliu, J; García-Muñoz, R; Olavarría, E; Zabalza, A	1
Cheson, BD	1
Andreeff, M; Calvert, LR; Faderl, S; Keating, M; McConkey, DJ; Niemer, I; Pahler, JC; Ruiz, S	1
Alkan, S; Hsi, ED; Kelley, TW; Srkalovic, G	1
Duechler, M; Hilgarth, M; Hoelbl, A; Hubmann, R; Schwarzmeier, JD; Shehata, M	1
Cebula, B; Duechler, M; Linke, A; Robak, T; Schwarzmeier, JD; Shehata, M; Smolewski, P	1
Cebula, B; Duechler, M; Grzybowska-Izydorczyk, O; Linke, A; Robak, T; Shehata, M; Smolewski, P	1
Gibson, SB; Hu, X; Johnston, JB; Kabore, AF; McCrea, K; Sun, J	1
De Coster, R; Dyer, MJ; Kohlhaas, SL; Majid, A; Monbaliu, J; Walewska, RJ; Wheat, LM	1
Byrd, JC; Esseltine, DL; Faderl, S; Flinn, IW; Gribben, J; Keating, MJ; O'Brien, S; Rai, K; Sheng, S	1
Chandra, J; Keating, M; Krupnik, Y; McConkey, D; Palladino, M; Ruiz, S	1
Benet, I; García-Conde, J; Jantus-Lewintre, E; Sarsotti, E; Terol, MJ	1
Snively, A	1
Chen, S; Dai, Y; Dent, P; Funk, VL; Grant, S; Kramer, LB	1

Reviews

23 review(s) available for pyrazines and B-Cell Chronic Lymphocytic Leukemia

Article	Year
BTK Inhibitors in Chronic Lymphocytic Leukemia. Current hematologic malignancy reports, 2021, Volume: 16, Issue:5 Topics: Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Development; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines	2021
Acalabrutinib: Nursing Considerations for Use in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma. Clinical journal of oncology nursing, 2021, 12-01, Volume: 25, Issue:6 Topics: Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pyrazines	2021
Acalabrutinib and its use in the treatment of chronic lymphocytic leukemia. Future oncology (London, England), 2022, Volume: 18, Issue:7 Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazines; Pyrazoles; Pyrimidines	2022
Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia. Expert review of hematology, 2022, Volume: 15, Issue:3 Topics: Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Protein Kinase Inhibitors; Pyrazines	2022
Cost-Effectiveness and Economic Burden Analyses on All First-Line Treatments of Chronic Lymphocytic Leukemia. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2022, Volume: 25, Issue:10 Topics: Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Cost-Benefit Analysis; Financial Stress; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Markov Chains; Pyrazines; Quality-Adjusted Life Years; Sulfonamides	2022
Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors. American journal of clinical dermatology, 2020, Volume: 21, Issue:6 Topics: Adenine; Administration, Cutaneous; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Biopsy; Drug Eruptions; Ecchymosis; Emollients; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Necrosis; Patient Education as Topic; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; Severity of Illness Index; Signal Transduction; Skin; Skin Care	2020
Comparison of acalabrutinib plus obinutuzumab, ibrutinib plus obinutuzumab and venetoclax plus obinutuzumab for untreated CLL: a network meta-analysis. Leukemia & lymphoma, 2020, Volume: 61, Issue:14 Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Network Meta-Analysis; Piperidines; Prospective Studies; Pyrazines; Sulfonamides	2020
Comparative Efficacy of Acalabrutinib in Frontline Treatment of Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-analysis. Clinical therapeutics, 2020, Volume: 42, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Network Meta-Analysis; Pyrazines; Randomized Controlled Trials as Topic	2020
Comparison Between Venetoclax-based and Bruton Tyrosine Kinase Inhibitor-based Therapy as Upfront Treatment of Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Network Meta-analysis. Clinical lymphoma, myeloma & leukemia, 2021, Volume: 21, Issue:4 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Mutation; Network Meta-Analysis; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Sulfonamides; Tumor Suppressor Protein p53	2021
Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies. British journal of haematology, 2021, Volume: 193, Issue:1 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Benzamides; Clinical Trials as Topic; Disease Progression; Hematologic Neoplasms; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Middle Aged; Piperidines; Practice Patterns, Physicians'; Pyrazines; Safety; Treatment Outcome; United States; United States Food and Drug Administration	2021
Chemotherapy-free frontline therapy for CLL: is it worth it? Hematology. American Society of Hematology. Education Program, 2020, 12-04, Volume: 2020, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pyrazines; Rituximab; Sulfonamides	2020
EMA Review of Acalabrutinib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia. The oncologist, 2021, Volume: 26, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Multicenter Studies as Topic; Pyrazines; Rituximab	2021
Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors. Hematology/oncology clinics of North America, 2021, Volume: 35, Issue:4 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Sulfonamides	2021
Targeting Bruton's Tyrosine Kinase in CLL. Frontiers in immunology, 2021, Volume: 12 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Mutation; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Signal Transduction; Treatment Outcome	2021
An update on acalabrutinib to treat chronic lymphocytic leukemia. Drugs of today (Barcelona, Spain : 1998), 2021, Volume: 57, Issue:7 Topics: Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Protein Kinase Inhibitors; Pyrazines; Pyrimidines	2021
Assessing the pharmacokinetics of acalabrutinib in the treatment of chronic lymphocytic leukemia. Expert opinion on drug metabolism & toxicology, 2021, Volume: 17, Issue:9 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazines	2021
BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects. Frontiers in immunology, 2021, Volume: 12 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Humans; Infection Control; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines	2021
Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib. Annals of hematology, 2017, Volume: 96, Issue:7 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Diarrhea; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nausea; Piperidines; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines; Signal Transduction; Sulfonamides	2017
Acalabrutinib: First Global Approval. Drugs, 2018, Volume: 78, Issue:1 Topics: Adult; Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug; Drug Approval; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Treatment Outcome; United States; United States Food and Drug Administration	2018
Acalabrutinib and its use in treatment of chronic lymphocytic leukemia. Future oncology (London, England), 2019, Volume: 15, Issue:6 Topics: Animals; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Protein Kinase Inhibitors; Pyrazines; Treatment Outcome	2019
Second-generation inhibitors of Bruton tyrosine kinase. Journal of hematology & oncology, 2016, 09-02, Volume: 9, Issue:1 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Drug Resistance, Neoplasm; Humans; Imidazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines	2016
[Novel medical treatment modalities in hematology]. Ugeskrift for laeger, 2008, Jun-09, Volume: 170, Issue:24 Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine	2008
Hematologic malignancies: new developments and future treatments. Seminars in oncology, 2002, Volume: 29, Issue:4 Suppl 13 Topics: Adenine Nucleotides; Alemtuzumab; Alkaloids; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cell Cycle; Cell Survival; Clofarabine; Cytosine; Dioxolanes; Flavonoids; Hematologic Neoplasms; Humans; Immunoconjugates; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Multiple Myeloma; NF-kappa B; Nitrogen Mustard Compounds; Oligonucleotides, Antisense; Peptide Hydrolases; Piperidines; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Remission Induction; Rituximab; Staurosporine; Thionucleotides	2002

Trials

27 trial(s) available for pyrazines and B-Cell Chronic Lymphocytic Leukemia

Article	Year
Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study. The Lancet. Oncology, 2021, Volume: 22, Issue:10 Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Boston; Bridged Bicyclo Compounds, Heterocyclic; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Progression-Free Survival; Pyrazines; Remission Induction; Sulfonamides; Time Factors	2021
Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1-2 study. The Lancet. Haematology, 2021, Volume: 8, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Neoplasm Recurrence, Local; Pyrazines; Treatment Outcome	2021
Circulating Tumor DNA-Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax. Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 10-03, Volume: 28, Issue:19 Topics: Antibodies, Monoclonal, Humanized; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Circulating Tumor DNA; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Pyrazines; Sulfonamides	2022
A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma. British journal of haematology, 2022, Volume: 199, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Benzamides; Disease Progression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell, Marginal Zone; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Pyrazines; Treatment Outcome	2022
Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial. The Lancet. Haematology, 2022, Volume: 9, Issue:10 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Cytoreduction Surgical Procedures; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplasm, Residual; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Sulfonamides	2022
Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. Blood, 2020, 04-09, Volume: 135, Issue:15 Topics: Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Pyrazines; Treatment Outcome	2020
Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia. Cancer discovery, 2020, Volume: 10, Issue:3 Topics: Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Proliferation; Drug Administration Schedule; Female; Humans; Interleukin-2; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pyrazines; Rituximab; Treatment Outcome	2020
Pharmacodynamic Analysis of BTK Inhibition in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib. Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 06-15, Volume: 26, Issue:12 Topics: Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Pyrazines	2020
Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 06-15, Volume: 26, Issue:12 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Imidazoles; Indazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Purines; Pyrazines; Pyrimidines; Quinazolinones; Salvage Therapy; Tissue Distribution	2020
Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib. Blood, 2020, 07-02, Volume: 136, Issue:1 Topics: Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Drug Administration Schedule; Enzyme Induction; Female; Headache; Hematologic Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Proteins; Pain; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazines; RNA-Seq; RNA, Messenger; RNA, Neoplasm; Transcriptome; Treatment Outcome	2020
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet (London, England), 2020, 04-18, Volume: 395, Issue:10232 Topics: Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chlorambucil; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Progression-Free Survival; Pyrazines	2020
ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020, 09-01, Volume: 38, Issue:25 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Benzamides; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Progression-Free Survival; Purines; Pyrazines; Quinazolinones; Rituximab	2020
Safety and antitumor activity of acalabrutinib for relapsed/refractory B-cell malignancies: A Japanese phase I study. Cancer science, 2021, Volume: 112, Issue:6 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Drug Administration Schedule; Female; Headache; Humans; Japan; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Purpura; Pyrazines; Survival Analysis; Treatment Outcome	2021
Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia. Haematologica, 2021, 09-01, Volume: 106, Issue:9 Topics: Adenine; Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazines	2021
Acalabrutinib in treatment-naive chronic lymphocytic leukemia. Blood, 2021, 06-17, Volume: 137, Issue:24 Topics: Adult; Aged; Aged, 80 and over; Benzamides; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Neoplasm Staging; Pyrazines; Tumor Suppressor Protein p53	2021
BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL. Blood, 2021, 11-11, Volume: 138, Issue:19 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Bispecific; Antigens, CD19; Antineoplastic Agents, Immunological; Benzamides; CD3 Complex; Female; Humans; Immune Checkpoint Inhibitors; Ipilimumab; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrazines; T-Lymphocytes	2021
Proapoptotic and immunomodulatory effects of SYK inhibitor entospletinib in combination with obinutuzumab in patients with chronic lymphocytic leukaemia. British journal of clinical pharmacology, 2022, Volume: 88, Issue:2 Topics: Antibodies, Monoclonal, Humanized; Humans; Indazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Recurrence, Local; Pyrazines; Receptors, Antigen, B-Cell; Syk Kinase	2022
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 11-01, Volume: 39, Issue:31 Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Prognosis; Prospective Studies; Pyrazines; Survival Rate	2021
Ibrutinib treatment improves T cell number and function in CLL patients. The Journal of clinical investigation, 2017, Aug-01, Volume: 127, Issue:8 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Animals; Antigens, CD; Antineoplastic Agents; Benzamides; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cohort Studies; CTLA-4 Antigen; Female; Humans; Immunosuppressive Agents; Immunotherapy; Interleukin-10; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Lymphocyte Activation; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Middle Aged; Piperidines; Programmed Cell Death 1 Receptor; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Immunologic; T-Lymphocytes	2017
Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study. Leukemia & lymphoma, 2019, Volume: 60, Issue:8 Topics: Aged; Aged, 80 and over; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Pyrazines; Receptors, Antigen, B-Cell; Recurrence; Retreatment; Treatment Outcome	2019
Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood advances, 2019, 05-14, Volume: 3, Issue:9 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Phosphorylation; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Treatment Outcome	2019
Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia. Applied health economics and health policy, 2019, Volume: 17, Issue:6 Topics: Antineoplastic Agents; Benzamides; Cost-Benefit Analysis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Pyrazines; Quality-Adjusted Life Years; State Medicine; Survival Analysis; United Kingdom	2019
An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood, 2015, Apr-09, Volume: 125, Issue:15 Topics: Aged; Aged, 80 and over; Disease-Free Survival; Female; Humans; Indazoles; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Syk Kinase	2015
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. The New England journal of medicine, 2016, Jan-28, Volume: 374, Issue:4 Topics: Administration, Oral; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Agents; Benzamides; Chromosome Deletion; Diarrhea; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Headache; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Recurrence	2016
Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL. Blood, 2016, 05-19, Volume: 127, Issue:20 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Class I Phosphatidylinositol 3-Kinases; Cytokines; Early Termination of Clinical Trials; Female; Humans; Indazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Proteins; Pneumonia; Protein Kinase Inhibitors; Purines; Pyrazines; Quinazolinones; Salvage Therapy; Syk Kinase	2016
Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia. Blood, 2016, 07-28, Volume: 128, Issue:4 Topics: Bridged Bicyclo Compounds, Heterocyclic; DNA-Activated Protein Kinase; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplasm Proteins; Nuclear Proteins; Purines; Pyrazines; Quinazolinones; Sulfonamides; TOR Serine-Threonine Kinases; Triazoles; Tumor Cells, Cultured; Vidarabine	2016
Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia. Cancer, 2006, Sep-01, Volume: 107, Issue:5 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Protease Inhibitors; Pyrazines; Treatment Outcome; Vidarabine	2006

Other Studies

58 other study(ies) available for pyrazines and B-Cell Chronic Lymphocytic Leukemia

Article	Year
Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients. Haematologica, 2022, 06-01, Volume: 107, Issue:6 Topics: Aged; Atrial Fibrillation; Benzamides; Humans; Hypertension; Leukemia, Lymphocytic, Chronic, B-Cell; Protein Kinase Inhibitors; Pyrazines	2022
Acalabrutinib monotherapy in patients with Richter transformation. The Lancet. Haematology, 2021, Volume: 8, Issue:12 Topics: Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Pyrazines	2021
Comment on: "Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients". Haematologica, 2022, 06-01, Volume: 107, Issue:6 Topics: Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pyrazines	2022
Response to Comment on: "Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients". Haematologica, 2022, 06-01, Volume: 107, Issue:6 Topics: Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pyrazines	2022
Is there a role for anti-CD20 antibodies in CLL? Hematology. American Society of Hematology. Education Program, 2021, 12-10, Volume: 2021, Issue:1 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antibodies, Monoclonal, Humanized; Antigens, CD20; Antineoplastic Agents; Antineoplastic Agents, Immunological; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Protein Kinase Inhibitors; Pyrazines; Rituximab; Sulfonamides	2021
Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia. Frontiers in immunology, 2021, Volume: 12 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Blood Platelets; Escherichia coli; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Platelet Activation; Platelet Aggregation; Protein Kinase Inhibitors; Pyrazines; Receptors, IgG; Staphylococcus aureus	2021
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia. Leukemia, 2022, Volume: 36, Issue:4 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chlorambucil; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pyrazines	2022
Recent data for acalabrutinib in chronic lymphocytic leukemia. Clinical advances in hematology & oncology : H&O, 2022, Volume: 20, Issue:1 Topics: Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pyrazines	2022
The highly selective Bruton tyrosine kinase inhibitor acalabrutinib leaves macrophage phagocytosis intact. Haematologica, 2022, 06-01, Volume: 107, Issue:6 Topics: Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Macrophages; Phagocytosis; Plant Leaves; Protein Kinase Inhibitors; Pyrazines	2022
Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib- and acalabrutinib-treated patients. Blood, 2022, 07-28, Volume: 140, Issue:4 Topics: Adenine; Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Neoplasm Recurrence, Local; Piperidines; Protein Kinase Inhibitors; Pyrazines	2022
Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib. Haematologica, 2023, 05-01, Volume: 108, Issue:5 Topics: Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Protein Kinase Inhibitors; Pyrazines	2023
Tolerability of acalabrutinib in patients with CLL: experience of a tertiary cancer care center. Leukemia & lymphoma, 2023, Volume: 64, Issue:5 Topics: Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines	2023
Evaluation of bleeding events in patients receiving acalabrutinib therapy. Leukemia, 2023, Volume: 37, Issue:7 Topics: Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pyrazines	2023
Acalabrutinib in chronic lymphocytic leukemia. Expert opinion on pharmacotherapy, 2023, Volume: 24, Issue:5 Topics: Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Protein Kinase Inhibitors; Pyrazines	2023
A matching-adjusted indirect comparison of acalabrutinib versus zanubrutinib in relapsed or refractory chronic lymphocytic leukemia. American journal of hematology, 2023, Volume: 98, Issue:12 Topics: Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Protein Kinase Inhibitors; Pyrazines	2023
2019 ASH Annual Meeting. The Lancet. Haematology, 2020, Volume: 7, Issue:1 Topics: Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Pyrazines	2020
Images in Vascular Medicine. Rumpel-Leede phenomenon in a patient with chronic lymphocytic leukemia treated with acalabrutinib. Vascular medicine (London, England), 2020, Volume: 25, Issue:3 Topics: Agammaglobulinaemia Tyrosine Kinase; Aged, 80 and over; Antineoplastic Agents; Benzamides; Capillary Fragility; Chronic Disease; Ecchymosis; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Protein Kinase Inhibitors; Pyrazines; Risk Factors; Stockings, Compression; Treatment Outcome; Venous Insufficiency	2020
Acalabrutinib for the initial treatment of chronic lymphocytic leukaemia. Lancet (London, England), 2020, 04-18, Volume: 395, Issue:10232 Topics: Antibodies, Monoclonal, Humanized; Benzamides; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pyrazines	2020
BTK Inhibitors in Cancer Patients with COVID-19: "The Winner Will be the One Who Controls That Chaos" (Napoleon Bonaparte). Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 07-15, Volume: 26, Issue:14 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Anti-Inflammatory Agents; Antineoplastic Agents; Benzamides; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Inflammation; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Macrophages; Pandemics; Piperidines; Pneumonia, Viral; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; SARS-CoV-2	2020
Acalabrutinib - a new option in CLL. Nature reviews. Clinical oncology, 2020, Volume: 17, Issue:7 Topics: Antibodies, Monoclonal, Humanized; Benzamides; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pyrazines	2020
Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19. British journal of haematology, 2020, Volume: 190, Issue:2 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Benzamides; Betacoronavirus; Coronavirus Infections; COVID-19; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pandemics; Piperidines; Pneumonia, Viral; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; SARS-CoV-2	2020
Occupy BTK: the key to controlling CLL. Blood, 2020, 07-02, Volume: 136, Issue:1 Topics: Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Protein Kinase Inhibitors; Pyrazines	2020
Second cancer incidence in CLL patients receiving BTK inhibitors. Leukemia, 2020, Volume: 34, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Benzamides; Female; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasms, Second Primary; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Retrospective Studies; Risk Factors; Young Adult	2020
Restricted mean survival time in patients with chronic lymphocytic leukemia treated with chemotherapy-free regimens as first line. Leukemia & lymphoma, 2021, Volume: 62, Issue:4 Topics: Adenine; Antibodies, Monoclonal, Humanized; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Network Meta-Analysis; Piperidines; Pyrazines; Sulfonamides; Survival Rate	2021
Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia. Leukemia & lymphoma, 2021, Volume: 62, Issue:5 Topics: Agammaglobulinaemia Tyrosine Kinase; Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Protein Kinase Inhibitors; Pyrazines	2021
Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies. Haematologica, 2021, 07-01, Volume: 106, Issue:7 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Humans; Indazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Pyrazines	2021
Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies. Leukemia, 2021, Volume: 35, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Pyrazines; Retrospective Studies; Survival Rate; United States	2021
Matching-adjusted indirect comparisons of safety and efficacy of acalabrutinib versus other targeted therapies in patients with treatment-naïve chronic lymphocytic leukemia. Leukemia & lymphoma, 2021, Volume: 62, Issue:10 Topics: Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pyrazines; Pyrimidines	2021
Mechanisms of resistance to BTK inhibitors in patients with chronic lymphocytic leukemia. Clinical advances in hematology & oncology : H&O, 2021, Volume: 19, Issue:7 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Humans; Imidazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines	2021
The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable Haematologica, 2017, Volume: 102, Issue:10 Topics: Antibodies; Antigens, CD20; Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines	2017
Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model. Clinical cancer research : an official journal of the American Association for Cancer Research, 2017, Oct-01, Volume: 23, Issue:19 Topics: Adenosine; Agammaglobulinaemia Tyrosine Kinase; Animals; Apoptosis; B-Lymphocytes; Benzamides; Cell Line, Tumor; Cell Proliferation; Class Ia Phosphatidylinositol 3-Kinase; Disease Models, Animal; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Neoplasm Proteins; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Quinolines; Tumor Microenvironment	2017
Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy. Leukemia, 2018, Volume: 32, Issue:4 Topics: Adenine; Adoptive Transfer; Animals; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Cell Movement; Chemokine CCL3; Chemokine CCL4; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteomics; Pyrazines; Pyrazoles; Pyrimidines; Signal Transduction; Sulfonamides	2018
Haematologica, 2018, Volume: 103, Issue:3 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; CD79 Antigens; Clonal Anergy; Endocytosis; Humans; Immunoglobulin M; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; Signal Transduction	2018
Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. Cancer, 2019, 02-15, Volume: 125, Issue:4 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Cell Transformation, Neoplastic; Cohort Studies; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; High-Throughput Nucleotide Sequencing; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Longitudinal Studies; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Mutation; Piperidines; Prognosis; Pyrazines; Pyrazoles; Pyrimidines	2019
A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor. Oncotarget, 2014, Feb-28, Volume: 5, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Drug Synergism; Humans; Indazoles; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Purines; Pyrazines; Quinazolinones; Signal Transduction; Syk Kinase	2014
Acalabrutinib for relapsed chronic lymphocytic leukaemia. The Lancet. Oncology, 2016, Volume: 17, Issue:2 Topics: Antineoplastic Agents; Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pyrazines; Recurrence; Retreatment	2016
Progress in Chronic Lymphocytic Leukemia with Targeted Therapy. The New England journal of medicine, 2016, Jan-28, Volume: 374, Issue:4 Topics: Antineoplastic Agents; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Sulfonamides	2016
New Agents to Treat Chronic Lymphocytic Leukemia. The New England journal of medicine, 2016, 06-02, Volume: 374, Issue:22 Topics: Antineoplastic Agents; Benzamides; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Protein-Tyrosine Kinases; Pyrazines	2016
The kinase inhibitors R406 and GS-9973 impair T cell functions and macrophage-mediated anti-tumor activity of rituximab in chronic lymphocytic leukemia patients. Cancer immunology, immunotherapy : CII, 2017, Volume: 66, Issue:4 Topics: Aged; Aged, 80 and over; Cell Proliferation; Cells, Cultured; Female; Humans; Indazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Activation; Macrophages; Male; Middle Aged; Oxazines; Phagocytosis; Phosphorylation; Pyrazines; Pyridines; Receptors, Antigen, T-Cell; Rituximab; Syk Kinase; T-Lymphocytes; ZAP-70 Protein-Tyrosine Kinase	2017
Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia. Leukemia, 2017, Volume: 31, Issue:10 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bcl-2-Like Protein 11; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mitochondria; Molecular Targeted Therapy; Neoplasm Proteins; Peptide Fragments; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrazoles; Pyrimidines; Sulfonamides	2017
The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood, 2008, Oct-01, Volume: 112, Issue:7 Topics: Animals; Antineoplastic Agents; Biphenyl Compounds; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Health; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Membrane Potential, Mitochondrial; Mice; Microscopy, Confocal; Molecular Mimicry; Nitrophenols; Piperazines; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Sulfonamides; Tissue Donors; Xenograft Model Antitumor Assays	2008
BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells. Leukemia, 2008, Volume: 22, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Drug Synergism; Humans; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Mitochondria; Phosphorylation; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrroles; Tumor Cells, Cultured	2008
Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib. Blood, 2008, Nov-01, Volume: 112, Issue:9 Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Boric Acids; Boronic Acids; Bortezomib; Cell Line, Transformed; Cell Line, Tumor; Cytochromes c; Diet; Flavonoids; Free Radical Scavengers; Humans; In Vitro Techniques; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Multiple Myeloma; Protease Inhibitors; Pyrazines; Quercetin	2008
Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells. Blood, 2009, Apr-30, Volume: 113, Issue:18 Topics: Acetylation; Antioxidants; Apoptosis; Boronic Acids; Bortezomib; Caspase 8; Drug Synergism; Drug Therapy, Combination; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Immunoblotting; Immunoprecipitation; Lactones; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Oxidative Stress; Protease Inhibitors; Proteasome Inhibitors; Protein Processing, Post-Translational; Pyrazines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Superoxides; Tumor Cells, Cultured; Vorinostat	2009
High-throughput detection of nuclear factor-kappaB activity using a sensitive oligo-based chemiluminescent enzyme-linked immunosorbent assay. International journal of cancer, 2010, Jul-15, Volume: 127, Issue:2 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; CD40 Ligand; Cell Nucleus; Enzyme-Linked Immunosorbent Assay; HeLa Cells; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Luminescent Measurements; Lymphocytes; NF-kappa B; Oligonucleotides; Pyrazines; Tumor Necrosis Factor-alpha	2010
Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells. Haematologica, 2010, Volume: 95, Issue:9 Topics: Apoptosis; Boronic Acids; Bortezomib; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Tumor Cells, Cultured; Ubiquitination	2010
[Modern times: back to past, back to future]. Medicina clinica, 2012, Jul-07, Volume: 139, Issue:4 Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Multiple Myeloma; Pyrazines; Rituximab; Vidarabine	2012
Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Oct-01, Volume: 9, Issue:12 Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Complement Membrane Attack Complex; Complement System Proteins; Cysteine Endopeptidases; Cytochromes c; DNA (Cytosine-5-)-Methyltransferases; Drug Resistance, Neoplasm; Enzyme Activation; Glucocorticoids; Glycoproteins; Humans; Inhibitor of Apoptosis Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Mitochondria; Multienzyme Complexes; Neoplasm Recurrence, Local; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteins; Pyrazines; Tumor Cells, Cultured; Vidarabine; X-Linked Inhibitor of Apoptosis Protein	2003
Treatment of human chronic lymphocytic leukemia cells with the proteasome inhibitor bortezomib promotes apoptosis. Leukemia research, 2004, Volume: 28, Issue:8 Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cysteine Endopeptidases; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Multienzyme Complexes; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Tumor Cells, Cultured	2004
Induction of apoptosis by proteasome inhibitors in B-CLL cells is associated with downregulation of CD23 and inactivation of Notch2. Leukemia, 2005, Volume: 19, Issue:2 Topics: Antigens, CD; Antineoplastic Agents; Apoptosis; Base Sequence; Boronic Acids; Bortezomib; Cell Line, Tumor; DNA Primers; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Receptor, Notch2; Receptors, Cell Surface; Receptors, IgE; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger	2005
In vitro cytotoxic effect of proteasome inhibitor bortezomib in combination with purine nucleoside analogues on chronic lymphocytic leukaemia cells. European journal of haematology, 2005, Volume: 74, Issue:5 Topics: Annexin A5; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Survival; Cladribine; Dose-Response Relationship, Drug; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Proteasome Inhibitors; Pyrazines; Tumor Cells, Cultured	2005
Additive cytotoxic effect of bortezomib in combination with anti-CD20 or anti-CD52 monoclonal antibodies on chronic lymphocytic leukemia cells. Leukemia research, 2006, Volume: 30, Issue:12 Topics: Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Caspase 3; Cell Death; Cells, Cultured; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Middle Aged; Pyrazines; Rituximab	2006
The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells. Apoptosis : an international journal on programmed cell death, 2006, Volume: 11, Issue:7 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; B-Lymphocytes; Boronic Acids; Bortezomib; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 3; Caspase 8; Caspases; Cell Line, Tumor; Cell Survival; Cysteine Proteinase Inhibitors; Drug Synergism; Gene Expression; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Leupeptins; Membrane Glycoproteins; Middle Aged; Proteasome Inhibitors; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha	2006
Inhibition of bortezomib-induced apoptosis by red blood cell uptake. Leukemia, 2006, Volume: 20, Issue:9 Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Erythrocytes; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pyrazines	2006
The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia. Molecular cancer therapeutics, 2006, Volume: 5, Issue:7 Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Humans; Lactones; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyrroles	2006
Bortezomib induces different apoptotic rates in B-CLL cells according to IgVH and BCL-6 mutations. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2006, Volume: 8, Issue:11 Topics: ADP-ribosyl Cyclase 1; Adult; Aged; Aged, 80 and over; Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspase Inhibitors; Caspases; Cysteine Proteinase Inhibitors; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Genes, Immunoglobulin; Humans; I-kappa B Kinase; I-kappa B Proteins; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Proteins; NF-kappa B; Nitriles; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-6; Pyrazines; Sulfones; Tumor Cells, Cultured; ZAP-70 Protein-Tyrosine Kinase	2006
Advances in the treatment of MDS, multiple myeloma, and CLL. ONS connect, 2007, Volume: 22, Issue:8 Suppl Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Monitoring; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Multiple Myeloma; Myelodysplastic Syndromes; Nurse's Role; Oncology Nursing; Prognosis; Pyrazines; Risk Assessment; Thalidomide	2007
Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Jan-15, Volume: 14, Issue:2 Topics: Acetylation; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Caspases; Cell Line, Tumor; Depsipeptides; Drug Synergism; Histone Deacetylases; Humans; Hydroxamic Acids; Leukemia, Lymphocytic, Chronic, B-Cell; NF-kappa B; Protease Inhibitors; Pyrazines; Sulfonamides	2008